During the plenary session of the European Parliament in Strasbourg, MEPs vote and debate on Health technology assessment (HTA), a report by Soledad CABEZÓN RUIZ (S&D, ES), extracts from the debate (1/10/2018) and illustrative shots on medicines. The results from the voteare: 576 in favor, 56 against and 41 abstentions. Statements by Soledad CABEZÓN RUIZ (S&D, ES), Rapporteur, Christos STYLIANIDES, Member of the EC in charge of Humanitarian Aid and Crisis Management, and Françoise GROSSETÊTE (EPP, FR). Illustrative shots: medicines production.

Strasbourg

debate

plenary session

vote

STYLIANIDES, Christos (CY, EC)

GROSSETÊTE, Françoise (EPP, FR)

CABEZÓN RUIZ, Soledad (S&D, ES)

healthcare safety (T)

Health technology assessment: extracts from the vote, from the debate (01/10) and illustrative shots

Vote on the report on Health Technology Assessement, report by Soledad CABEZ&Oacute;N RUIZ (S&amp;D, ES). Cutaways on rapporteur.

Digital screeen with results: 576 votes in favor, 56 against and 41 abstentions.

SOUNDBITE (Spanish), Soledad CABEZ&Oacute;N RUIZ (S&amp;D, ES), Rapporteur, This proposal, particularly thanks to the amendments of the EP, will help improve quality and ensure better alignment of medical needs and research while contributing to the sustainability of health systems. Taken as a whole, it will improve European citizens access to medicines and new health services.<em> </em>

SOUNDBITE (English), Christos STYLIANIDES, Member of the EC in charge of Humanitarian Aid and Crisis Management, Patients lie at the very heart of this proposal which aims for a more efficient transparent and effective EU HTA and these new model of EU co-operation has a clear potential to facilitate better access to innovative health technologies<em>.</em>

SOUNDBITE (French), Fran&ccedil;oise GROSSET&Ecirc;TE (EPP, FR), We are talking about a common scientific assessment regarding the therapeutic added value of a new technology regarding but relative to existing ones. And that's a task which will make it easier to promote treatment with higher added value and enhance patients access to innovative treatment.

Illustrative shots: medicines production (5 shots)